研究论文

新型香豆素衍生物的合成及其抗非小细胞肺癌活性研究

  • 朱凯 ,
  • 邢琳 ,
  • 李璐璐 ,
  • 范君婷 ,
  • 盛瑞隆 ,
  • 郭锐华
展开
  • a上海海洋大学食品学院海洋药物教研室 上海 201306;
    b南京医科大学药学院 南京 211166;
    cCQM - Centro de Química da Madeira, Universidade da Madeira, Campus da Penteada Portugal 9000-390

收稿日期: 2026-03-30

  修回日期: 2026-04-25

  网络出版日期: 2026-06-04

基金资助

国家自然科学基金(No.82173731 & No.81502955)资助项目.

Synthesis and Anti-Non-Small Cell Lung Cancer Activity of Novel Coumarin Derivatives

  • Zhu Kai ,
  • Xing Lin ,
  • Li Lulu ,
  • Fan Junting ,
  • Sheng Ruilong ,
  • Guo Ruihua
Expand
  • a Department of Marine Drugs, College of Food Science and Technology, Shanghai Ocean University, Shanghai, 201306;
    b Department of Pharmaceutical Analysis, School of Pharmacy, Nanjing Medical University, Nanjing, 211166;
    c CQM - Centro de Química da Madeira, Universidade da Madeira, Campus da Penteada, Portugal, 9000-390

Received date: 2026-03-30

  Revised date: 2026-04-25

  Online published: 2026-06-04

Supported by

National Natural Science Foundation of China (No. 82173731 & No.81502955).

摘要

本文合成了一系列新型香豆素衍生物1-15,并评价了它们对A549细胞的抗癌活性。多数衍生物表现出中等程度的抑制活性。其中,衍生物2、13-15具有显著的生物活性,IC50值范围为4.7±0.7至17.9±2.1 μM。衍生物13在体外对A549细胞具有显著的抑制活性,IC50值为4.7±0.7 µM。对衍生物13进行网络药理学研究,共得到166个交集靶点。PPI网络分析表明,EGFR是关键靶点;富集性分析提示,衍生物13可能通过多靶点调控与细胞存活及增殖相关的关键信号通路,从而发挥抗肺癌的作用。使用分子对接进行验证发现,衍生物13对EGFR的对接得分为-7.93 kcal/mol。分子对接结果显示,衍生物13能够与EGFR蛋白的Ser-784、Arg-748和Lys-754残基形成相互作用,这可能是其发挥调控作用的潜在机制。同时,衍生物13显著影响了A549细胞周期,使之阻滞于G0/G1期。研究结果表明,衍生物13有望成为抗非小细胞肺癌的先导化合物。

本文引用格式

朱凯 , 邢琳 , 李璐璐 , 范君婷 , 盛瑞隆 , 郭锐华 . 新型香豆素衍生物的合成及其抗非小细胞肺癌活性研究[J]. 有机化学, 0 : 0 . DOI: 10.6023/cjoc202603042

Abstract

A series of novel coumarin derivatives 1-15 were synthesized and evaluated for their anticancer activity against A549 cell. Most derivatives showed moderate inhibitory activities. Among them, derivatives 2, 13-15 presented remarkable bioactivities with IC50 values range from 4.7±0.7 to 17.9±2.1 μM. Derivative 13 exhibited remarkable inhibitory activity against A549 (IC50 = 4.7±0.7 µM) in vitro. Network pharmacology analysis of derivative 13 yielded a total of 166 intersecting targets. The PPI network identified EGFR as a key target, and enrichment analysis suggested that derivative 13 may exert its anti-lung cancer effects through multi target regulation of key signaling pathways associated with cell survival and proliferation. Docking analysis showed that derivative 13 exhibited a docking score of -7.93 kcal/mol for EGFR. It was found to exert potential regulatory effects on the EGFR by interacting with Ser-784, Arg-748, and Lys-754 residues. Additionally, derivative 13 significantly affected the cell cycle of A549 cells, inducing G0/G1-phase arrest. Thus, these results suggest that derivative 13 is a promising lead compound for the treatment of non-small cell lung cancer.

参考文献

[1] Siegel R.L.; Miller K.D.; Jemal A. CA Cancer J.Clin. 2018, 68, 7-30.
[2] Zhang Y.; Cheng K.; Xu B.; Shi J.; Qiang J.; Shi S.; Yi Y.; Li H.; Jin T.; Guo R.; Wu Y.; Liu Z.; Wei X.; Huang J.A.; Yang X.H.Front Cell Dev. Biol. 2020, 8, 652.
[3] Testa U.; Castelli G.; Pelosi E. Cancers (Basel). 2018, 10, 248.
[4] An B.; Pan T.; Hu J.; Pang Y.; Huang L.; Chan A.S.C.; Li, X.; Yan, J. Eur. J. Med. Chem. 2019, 183, 111709.
[5] Dandriyal J.; Singla R.; Kumar M.; Jaitak V. Eur.J. Med. Chem. 2016, 119, 141-168.
[6] Ding J.; Liu J.; Zhang Z.; Guo J.; Cheng M.; Wan Y.; Wang R.; Fang Y.; Guan Z.; Jin Y.; Xie S.S. Bioorg. Chem. 2020, 101, 104023.
[7] Rosselli S.; Maggio A.M.; Faraone N.; Spadaro V.; Morris-Natschke, S.L.; Bastow, K.F.; Lee, K.-H.; Bruno, M. Nat. Prod. Commun. 2009, 4, 1701-1706.
[8] Bansal Y.; Sethi P.; Bansal G. Med. Chem. Res. 2013, 22, 3049-3060.
[9] Amin K.M.; Awadalla F.M.; Eissa A.A.M.; Abou-Seri, S.M.; Hassan, G.S. Bioorgan. Med. Chem. 2011, 19, 6087-6097.
[10] Basanagouda M.; Jambagi V.B.; Barigidad N.N.; Laxmeshwar S.S.; Devaru V.; Narayana C. Eur.J. Med. Chem. 2014, 74, 225-233.
[11] Wang Y.; Wang J.; Fu Z.; Sheng R.; Wu W.; Fan J.; Guo R.Bioorg Chem. 2020, 104, 104342.
[12] Thakur A.; Singla R.; Jaitak V. Eur.J. Med. Chem. 2015, 101, 476-495.
[13] Bhattarai N.; Kumbhar A. A.; Pokharel Y. R.; Yadav P. N.Mini Rev. Med. Chem. 2021, 21, 2996-3029.
[14] Ekowati H., Astuti I., Mustofa M. Indo.J. Chem. 2010, 10, 247-251.
[15] Katkevi S.M.; Kontijevskis A.; Mutule I. Chem. Heterocycl. Compd. 2007, 43, 151-159.
[16] Tiftikçi E.; Erk Ç. T.J. Heterocyclic. Chem. 2010, 41, 867-871.
[17] Madhav J.V.; Kuarm B.S.; Someshwar P. J. Chem. Res. 2010, 2008, 867-871.
[18] Lu Z.L.; Neverov A.A.; Brown, R.S. Org. Biomol. Chem. 2005, 3, 3379-3387.
[19] Shen Q.; Peng Q.; Shao J.; Liu X.; Huang Z.; Pu X.; Ma L.; Li Y.M.; Chan A.S.; Gu L. Eur.J. Med. Chem. 2005, 40, 1307-1315.
[20] Fall Y.; Santana L.; Uriarte E. J. Heterocyclic. Chem. 2001, 38, 1231-1232.
[21] Timonen J.M.; Nieminen R.M.; Sareila O. Eur.J. Med. Chem. 2011, 46, 3845-3850.
[22] Pisani L.; Muncipinto G.; Miscioscia T.F.; Nicolloti O.; Leonetti F.; Catto M.; Caccia C.; Salvati P.; Soto-Otero, R.; MendezAlvarez, E.; Passeleu, C.; Carotti, A. J. Med. Chem. 2009, 52, 6685-6706.
[23] Sun X.J.; Xing L.; Yuan J.Y.; Wang E.X.; Ding Y.X.; Sheng R.L.; Wang F.; Wu W.H.; Yang X.W.H.; Guo, R.H. Fitoterapia. 2023, 167, 105504.
[24] Yang J.; Mu W.W.; Liu, G.Y. Eur. J. Pharmacol. 2020, 888, 173396.
[25] Patil J.V.; Soman S.S.; Umar S.; Girase P.; Balakrishnan S.ChemistrySelect. 2024, 9, 1-14.
文章导航

/